{"id":"tetanus-diphtheria-pertussis-vaccine","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Injection site pain, redness, or swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Fatigue or malaise"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2109219","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated toxoids (for tetanus and diphtheria) and acellular pertussis antigens that trigger both humoral and cell-mediated immune responses. These responses generate protective antibodies (particularly IgG) against the bacterial toxins and surface antigens, providing immunity against these three serious bacterial infections. Booster doses maintain protective antibody titers throughout life.","oneSentence":"The tetanus-diphtheria-pertussis vaccine stimulates the immune system to produce antibodies and cellular immunity against toxins and pathogens from Clostridium tetani, Corynebacterium diphtheriae, and Bordetella pertussis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:51.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of tetanus"},{"name":"Prevention of diphtheria"},{"name":"Prevention of pertussis (whooping cough)"}]},"trialDetails":[{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT07097012","phase":"PHASE4","title":"Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-16","conditions":"RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy","enrollment":60},{"nctId":"NCT07444502","phase":"","title":"Safety Monitoring of Boostagen® Vaccine in Thailand","status":"COMPLETED","sponsor":"BioNet-Asia Co., Ltd.","startDate":"2017-06-30","conditions":"Pertussis (Whooping Cough), Tetanus, Diphtheria","enrollment":10727},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT04294433","phase":"PHASE4","title":"Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children","status":"COMPLETED","sponsor":"Laval University","startDate":"2018-06-11","conditions":"Hepatitis B","enrollment":431},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT02118961","phase":"PHASE3","title":"Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":446},{"nctId":"NCT03188692","phase":"PHASE3","title":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-06-23","conditions":"Immunization","enrollment":33},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT05116241","phase":"PHASE2","title":"Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2021-11-11","conditions":"Bordetella Pertussis, Whooping Cough","enrollment":368},{"nctId":"NCT07213089","phase":"PHASE2, PHASE3","title":"Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"BioNet-Asia Co., Ltd.","startDate":"2020-07-13","conditions":"Pertussis Whooping Cough","enrollment":290},{"nctId":"NCT06798831","phase":"PHASE3","title":"Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNet-Asia Co., Ltd.","startDate":"2025-02-08","conditions":"Pertussis Vaccine","enrollment":2399},{"nctId":"NCT06639074","phase":"PHASE2","title":"Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-11-08","conditions":"Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma","enrollment":78},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04300192","phase":"PHASE4","title":"Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-01-27","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":273},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT06857370","phase":"PHASE3","title":"Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-03-23","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":780},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT02783170","phase":"PHASE4","title":"Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-09","conditions":"Pregnancy","enrollment":81},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT05662852","phase":"PHASE2","title":"Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors","status":"COMPLETED","sponsor":"ABO Holdings, Inc.","startDate":"2023-05-05","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination","enrollment":100},{"nctId":"NCT07005726","phase":"PHASE4","title":"BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa","status":"ENROLLING_BY_INVITATION","sponsor":"Bandim Health Project","startDate":"2025-05-09","conditions":"Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines","enrollment":6000},{"nctId":"NCT03589768","phase":"PHASE2","title":"Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-24","conditions":"Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation","enrollment":399},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06056050","phase":"PHASE1","title":"A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":180},{"nctId":"NCT06708286","phase":"PHASE2, PHASE3","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1820},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT03562377","phase":"PHASE2","title":"Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-07-13","conditions":"Atopic Dermatitis","enrollment":215},{"nctId":"NCT05827874","phase":"PHASE1","title":"A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT05028634","phase":"PHASE3","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-11-11","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT06817187","phase":"PHASE3","title":"Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-16","conditions":"Streptococcus Pneumoniae Infections","enrollment":1110},{"nctId":"NCT06815250","phase":"NA","title":"Enhancing Maternal Vaccine Knowledge and Uptake: the InTroDuce-Programme Trial","status":"NOT_YET_RECRUITING","sponsor":"Universiti Putra Malaysia","startDate":"2025-06-01","conditions":"Vaccination Uptake, Knowledge, Tetanus, Diphtheria and Acellular Pertussis Vaccination","enrollment":351},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT05613205","phase":"PHASE1","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-28","conditions":"Typhoid Fever","enrollment":97},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT03165981","phase":"PHASE4","title":"Fever After Simultaneous Versus Sequential Vaccination in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-25","conditions":"Fever After Vaccination, Fever, Febrile Seizure","enrollment":221},{"nctId":"NCT02374450","phase":"","title":"A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Malaria","enrollment":36366},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT04138056","phase":"PHASE2","title":"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-11-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":509},{"nctId":"NCT04056117","phase":"PHASE1, PHASE2","title":"A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2019-09-02","conditions":"Shigellosis","enrollment":596},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06466629","phase":"","title":"The Optimal Timing of Vaccination in Pregnancy","status":"RECRUITING","sponsor":"Elke Leuridan, MD, PhD","startDate":"2021-07-01","conditions":"Pertussis/Whooping Cough","enrollment":96},{"nctId":"NCT04766086","phase":"PHASE2","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-12","conditions":"Group B Streptococcus Infections","enrollment":306},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT06313762","phase":"NA","title":"Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2022-01-18","conditions":"Pain, Pediatrics, Vaccination","enrollment":300},{"nctId":"NCT03530124","phase":"PHASE4","title":"Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-17","conditions":"Apnea, Apnea Neonatal, Prematurity","enrollment":223},{"nctId":"NCT03457194","phase":"","title":"Optimising Protection for Pregnant Women and Infants With Maternal Vaccination","status":"UNKNOWN","sponsor":"Women's and Children's Hospital, Australia","startDate":"2018-08-28","conditions":"Obesity","enrollment":73},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT02458183","phase":"PHASE3","title":"Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-02-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":476},{"nctId":"NCT05870618","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT05870631","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT05040802","phase":"","title":"Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-06-02","conditions":"Pertussis (Whooping Cough)","enrollment":462},{"nctId":"NCT05169905","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-02","conditions":"Respiratory Syncytial Virus Infections","enrollment":9},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT01568060","phase":"","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":645},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21},{"nctId":"NCT05183516","phase":"PHASE1, PHASE2","title":"Tdap and Biomarkers of Alzheimer's Disease","status":"UNKNOWN","sponsor":"Mindful Diagnostics and Therapeutics, LLC","startDate":"2023-05-01","conditions":"Alzheimer Disease, Late Onset","enrollment":50},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT03463577","phase":"","title":"The Safety of Boostrix Following Routine Immunization of Pregnant Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-13","conditions":"Whooping Cough","enrollment":65783},{"nctId":"NCT01137435","phase":"PHASE4","title":"Post Marketing Surveillance for ADACEL™ in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":659},{"nctId":"NCT01439165","phase":"PHASE4","title":"Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-11","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":1330},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT00855855","phase":"","title":"Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-02","conditions":"Haemophilus Infections, Diphtheria, Tetanus","enrollment":20830},{"nctId":"NCT03958799","phase":"PHASE1","title":"A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-06-26","conditions":"Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)","enrollment":71},{"nctId":"NCT02274285","phase":"PHASE3","title":"DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-10","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":424},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02817451","phase":"PHASE3","title":"DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-14","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":53},{"nctId":"NCT02428491","phase":"PHASE3","title":"Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-04-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":354},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tetanus-diphtheria-pertussis vaccine","genericName":"Tetanus-diphtheria-pertussis vaccine","companyName":"Tan Tock Seng Hospital","companyId":"tan-tock-seng-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"The tetanus-diphtheria-pertussis vaccine stimulates the immune system to produce antibodies and cellular immunity against toxins and pathogens from Clostridium tetani, Corynebacterium diphtheriae, and Bordetella pertussis. Used for Prevention of tetanus, Prevention of diphtheria, Prevention of pertussis (whooping cough).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}